WO2015160219A1 - 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 - Google Patents
피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 Download PDFInfo
- Publication number
- WO2015160219A1 WO2015160219A1 PCT/KR2015/003881 KR2015003881W WO2015160219A1 WO 2015160219 A1 WO2015160219 A1 WO 2015160219A1 KR 2015003881 W KR2015003881 W KR 2015003881W WO 2015160219 A1 WO2015160219 A1 WO 2015160219A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- extract
- copd
- chronic obstructive
- fraction
- composition
- Prior art date
Links
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 title claims abstract description 130
- 239000000284 extract Substances 0.000 title claims abstract description 120
- 150000001875 compounds Chemical class 0.000 title claims abstract description 98
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 29
- 241000115499 Pistacia weinmaniifolia Species 0.000 title claims abstract description 22
- 230000003405 preventing effect Effects 0.000 title claims abstract description 18
- 235000004760 Pistacia weinmaniifolia Nutrition 0.000 title claims abstract description 8
- 239000000203 mixture Substances 0.000 claims abstract description 64
- 230000001684 chronic effect Effects 0.000 claims abstract description 48
- 235000013305 food Nutrition 0.000 claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 32
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims abstract description 25
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims abstract description 24
- 206010014561 Emphysema Diseases 0.000 claims abstract description 21
- 206010006451 bronchitis Diseases 0.000 claims abstract description 19
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 19
- 206010006448 Bronchiolitis Diseases 0.000 claims abstract description 18
- 210000004969 inflammatory cell Anatomy 0.000 claims abstract description 16
- 208000037976 chronic inflammation Diseases 0.000 claims abstract description 7
- 208000038016 acute inflammation Diseases 0.000 claims abstract description 6
- 230000006022 acute inflammation Effects 0.000 claims abstract description 6
- 230000006020 chronic inflammation Effects 0.000 claims abstract description 6
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims abstract 2
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 39
- 210000004027 cell Anatomy 0.000 claims description 39
- 238000004519 manufacturing process Methods 0.000 claims description 32
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 31
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 24
- 241000543704 Pistacia Species 0.000 claims description 24
- 235000003445 Pistacia Nutrition 0.000 claims description 24
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 24
- 210000000440 neutrophil Anatomy 0.000 claims description 23
- 230000036541 health Effects 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 17
- 230000005764 inhibitory process Effects 0.000 claims description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 claims description 12
- 230000002265 prevention Effects 0.000 claims description 11
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 10
- 230000002829 reductive effect Effects 0.000 claims description 10
- 102100034871 C-C motif chemokine 8 Human genes 0.000 claims description 8
- 101710155833 C-C motif chemokine 8 Proteins 0.000 claims description 8
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000012046 mixed solvent Substances 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- 210000000621 bronchi Anatomy 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 210000004204 blood vessel Anatomy 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 23
- 238000010171 animal model Methods 0.000 abstract description 13
- 229940124597 therapeutic agent Drugs 0.000 abstract description 11
- 101710151803 Mitochondrial intermediate peptidase 2 Proteins 0.000 abstract description 8
- 230000008901 benefit Effects 0.000 abstract description 6
- 241000196324 Embryophyta Species 0.000 abstract description 5
- 230000008595 infiltration Effects 0.000 abstract description 3
- 238000001764 infiltration Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000000463 material Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 33
- 230000006698 induction Effects 0.000 description 31
- 102100040247 Tumor necrosis factor Human genes 0.000 description 23
- 239000000401 methanolic extract Substances 0.000 description 23
- 239000002904 solvent Substances 0.000 description 18
- 230000002401 inhibitory effect Effects 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 17
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 16
- 239000000843 powder Substances 0.000 description 16
- 208000019693 Lung disease Diseases 0.000 description 14
- 241000208125 Nicotiana Species 0.000 description 14
- 230000000391 smoking effect Effects 0.000 description 14
- 241000209502 Pistia Species 0.000 description 13
- 230000001154 acute effect Effects 0.000 description 13
- 238000000605 extraction Methods 0.000 description 13
- 210000004072 lung Anatomy 0.000 description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
- 238000004458 analytical method Methods 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 101000972282 Homo sapiens Mucin-5AC Proteins 0.000 description 10
- 102100022496 Mucin-5AC Human genes 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 9
- 235000019504 cigarettes Nutrition 0.000 description 9
- 238000010586 diagram Methods 0.000 description 9
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 239000012530 fluid Substances 0.000 description 9
- 238000009472 formulation Methods 0.000 description 9
- 230000004054 inflammatory process Effects 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 238000010828 elution Methods 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- 108010012236 Chemokines Proteins 0.000 description 7
- 102000019034 Chemokines Human genes 0.000 description 7
- -1 IL-1β Proteins 0.000 description 7
- 206010036790 Productive cough Diseases 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 239000002775 capsule Substances 0.000 description 7
- 238000007796 conventional method Methods 0.000 description 7
- 238000011161 development Methods 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 239000000779 smoke Substances 0.000 description 7
- 208000024794 sputum Diseases 0.000 description 7
- 210000003802 sputum Anatomy 0.000 description 7
- 238000004704 ultra performance liquid chromatography Methods 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 230000003833 cell viability Effects 0.000 description 6
- 239000002038 ethyl acetate fraction Substances 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 239000008187 granular material Substances 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000002685 pulmonary effect Effects 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 206010070834 Sensitisation Diseases 0.000 description 5
- 150000001298 alcohols Chemical class 0.000 description 5
- 150000001720 carbohydrates Chemical class 0.000 description 5
- 235000014633 carbohydrates Nutrition 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 230000003013 cytotoxicity Effects 0.000 description 5
- 231100000135 cytotoxicity Toxicity 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000001914 filtration Methods 0.000 description 5
- 230000028709 inflammatory response Effects 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 239000006187 pill Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 230000008313 sensitization Effects 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 239000011782 vitamin Substances 0.000 description 5
- 235000013343 vitamin Nutrition 0.000 description 5
- 229930003231 vitamin Natural products 0.000 description 5
- 229940088594 vitamin Drugs 0.000 description 5
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 4
- 206010011224 Cough Diseases 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 238000003820 Medium-pressure liquid chromatography Methods 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 208000006673 asthma Diseases 0.000 description 4
- 210000003123 bronchiole Anatomy 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 235000008504 concentrate Nutrition 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 235000013365 dairy product Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 235000013355 food flavoring agent Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 235000015203 fruit juice Nutrition 0.000 description 4
- 239000002044 hexane fraction Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- OKKJLVBELUTLKV-VMNATFBRSA-N methanol-d1 Chemical compound [2H]OC OKKJLVBELUTLKV-VMNATFBRSA-N 0.000 description 4
- 239000003607 modifier Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 208000000884 Airway Obstruction Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 240000005979 Hordeum vulgare Species 0.000 description 3
- 235000007340 Hordeum vulgare Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 244000269722 Thea sinensis Species 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 235000008429 bread Nutrition 0.000 description 3
- 239000002034 butanolic fraction Substances 0.000 description 3
- 235000014121 butter Nutrition 0.000 description 3
- 238000010609 cell counting kit-8 assay Methods 0.000 description 3
- 239000002036 chloroform fraction Substances 0.000 description 3
- 208000013116 chronic cough Diseases 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- 235000015243 ice cream Nutrition 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 208000027866 inflammatory disease Diseases 0.000 description 3
- 230000002427 irreversible effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 235000012149 noodles Nutrition 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 231100000915 pathological change Toxicity 0.000 description 3
- 230000036285 pathological change Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000000770 proinflammatory effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 2
- 108010011485 Aspartame Proteins 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 241001107116 Castanospermum australe Species 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 235000004347 Perilla Nutrition 0.000 description 2
- 244000124853 Perilla frutescens Species 0.000 description 2
- 239000012979 RPMI medium Substances 0.000 description 2
- 108010087230 Sincalide Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 244000228451 Stevia rebaudiana Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 235000013334 alcoholic beverage Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000037005 anaesthesia Effects 0.000 description 2
- 239000012223 aqueous fraction Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 235000021279 black bean Nutrition 0.000 description 2
- 235000007215 black sesame Nutrition 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 235000021329 brown rice Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 235000013339 cereals Nutrition 0.000 description 2
- 239000005482 chemotactic factor Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 239000003246 corticosteroid Substances 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 229910001873 dinitrogen Inorganic materials 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 230000003090 exacerbative effect Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 239000003862 glucocorticoid Substances 0.000 description 2
- NDJKXXJCMXVBJW-UHFFFAOYSA-N heptadecane Chemical compound CCCCCCCCCCCCCCCCC NDJKXXJCMXVBJW-UHFFFAOYSA-N 0.000 description 2
- 238000002114 high-resolution electrospray ionisation mass spectrometry Methods 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 239000005445 natural material Substances 0.000 description 2
- 231100001083 no cytotoxicity Toxicity 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000013618 particulate matter Substances 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229910052698 phosphorus Inorganic materials 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 235000013550 pizza Nutrition 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 150000004804 polysaccharides Chemical class 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- 235000013580 sausages Nutrition 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 235000011888 snacks Nutrition 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 229940037128 systemic glucocorticoids Drugs 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 229960000278 theophylline Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 238000002137 ultrasound extraction Methods 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 235000015192 vegetable juice Nutrition 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- PFWLFWPASULGAN-UHFFFAOYSA-N 7-methylxanthine Chemical compound N1C(=O)NC(=O)C2=C1N=CN2C PFWLFWPASULGAN-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- 206010001382 Adrenal suppression Diseases 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282817 Bovidae Species 0.000 description 1
- 206010006440 Bronchial obstruction Diseases 0.000 description 1
- 229940124697 COPD therapeutics Drugs 0.000 description 1
- 108050006947 CXC Chemokine Proteins 0.000 description 1
- 102000019388 CXC chemokine Human genes 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 240000001879 Digitalis lutea Species 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000001512 FEMA 4601 Substances 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004378 Glycyrrhizin Substances 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 101710151805 Mitochondrial intermediate peptidase 1 Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000003945 NF-kappa B Human genes 0.000 description 1
- 108010057466 NF-kappa B Proteins 0.000 description 1
- 208000011623 Obstructive Lung disease Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- HELXLJCILKEWJH-SEAGSNCFSA-N Rebaudioside A Natural products O=C(O[C@H]1[C@@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1)[C@@]1(C)[C@@H]2[C@](C)([C@H]3[C@@]4(CC(=C)[C@@](O[C@H]5[C@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@@H](O[C@H]6[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O6)[C@H](O)[C@@H](CO)O5)(C4)CC3)CC2)CCC1 HELXLJCILKEWJH-SEAGSNCFSA-N 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 241000555745 Sciuridae Species 0.000 description 1
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 230000009798 acute exacerbation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000015197 apple juice Nutrition 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 108010030694 avidin-horseradish peroxidase complex Proteins 0.000 description 1
- 229940124748 beta 2 agonist Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000003182 bronchodilatating effect Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 235000015190 carrot juice Nutrition 0.000 description 1
- 238000003570 cell viability assay Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 description 1
- 229960002327 chloral hydrate Drugs 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 231100000762 chronic effect Toxicity 0.000 description 1
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 235000012495 crackers Nutrition 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- HELXLJCILKEWJH-UHFFFAOYSA-N entered according to Sigma 01432 Natural products C1CC2C3(C)CCCC(C)(C(=O)OC4C(C(O)C(O)C(CO)O4)O)C3CCC2(C2)CC(=C)C21OC(C1OC2C(C(O)C(O)C(CO)O2)O)OC(CO)C(O)C1OC1OC(CO)C(O)C(O)C1O HELXLJCILKEWJH-UHFFFAOYSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 description 1
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 description 1
- 229960004949 glycyrrhizic acid Drugs 0.000 description 1
- 235000019410 glycyrrhizin Nutrition 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 235000019674 grape juice Nutrition 0.000 description 1
- 208000037824 growth disorder Diseases 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000012676 herbal extract Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 230000031723 negative regulation of chemokine production Effects 0.000 description 1
- 230000031990 negative regulation of inflammatory response Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 231100000065 noncytotoxic Toxicity 0.000 description 1
- 230000002020 noncytotoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 238000009160 phytotherapy Methods 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000009325 pulmonary function Effects 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 235000019203 rebaudioside A Nutrition 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 229960004017 salmeterol Drugs 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 208000013220 shortness of breath Diseases 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 235000015193 tomato juice Nutrition 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 230000006433 tumor necrosis factor production Effects 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 230000004855 vascular circulation Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/22—Anacardiaceae (Sumac family), e.g. smoketree, sumac or poison oak
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
Definitions
- the present invention relates to a composition for inhibiting chronic obstructive pulmonary disease, comprising a pistasia Wayne Manifolia extract, a fraction thereof, or a compound isolated therefrom, and more specifically, a Pistacia Wayne Manifolia extract, a fraction thereof, or The present invention relates to a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, comprising a separated compound, a food composition for preventing or improving chronic obstructive pulmonary disease, and the separated compound.
- COPD Chronic Obstructive Pulmonary Disease
- COPD is a disease caused by pathological changes in bronchioles and pulmonary parenchyma by airway and lung parenchymal inflammation, characterized by obstructive bronchiolitis and emphysema (pulmonary parenchymal destruction).
- Types of chronic obstructive pulmonary disease include chronic obstructive bronchitis, chronic bronchiolitis and emphysema. Smoking is considered to be the most important cause of COPD.
- Smoking acts as a strong toxicant in lung tissue, promoting the production of oxides, proinflammatory and chemotactic factors, which promotes excessive migration of inflammatory cells such as neutrophils. Inflammatory cells migrated into the lung tissue also secrete many inflammatory mediators, further exacerbating inflammation in the lung tissue. TNF- ⁇ , MIP-1, CXCL-1 and the like are mainly known as mediators to promote the inflammatory response, and are used as an important marker in the inflammatory reaction caused by tobacco smoke.
- therapeutic substances used for chronic obstructive pulmonary disease have been mainly developed to improve inflammation in lung tissue, and mainly steroid agents and anti-inflammatory agents are used. However, these therapeutic agents cause various side effects such as immunosuppression and resistance, and are not suitable for patients with chronic obstructive pulmonary disease requiring long-term treatment.
- COPD has been used for the treatment of inflammatory diseases with anti-inflammatory or bronchodilating effects. Many of these existing therapies require caution when used with many side effects.
- Representative therapeutic agents include glucocorticoids, leukotriene modifiers, theophylline, and the like. Glucocorticoids are potent in effect but not selective but rather inhibit all immune and anti-inflammatory responses. Treatment is taking place.
- Rukotriene modifiers leukotriene modifiers
- Deophylline (theophylline) is not good in terms of effectiveness and there is a problem that there is a concern of side effects.
- corticosteroids Although corticosteroids have excellent therapeutic effects, they are known to cause adrenal suppression, decreased bone density, growth disorders, eye and skin complications, and increased collagen synthesis in the long term. . Long-lasting beta-2 agonists, such as salmeterol and formeterol, have been shown to have a protective effect against seizures, but in some cases have been warned of death. . Due to such various side effects, conventional therapeutic agents for inflammatory diseases need careful consideration in their use, and there is an urgent need for development of therapeutic agents having excellent effects and low side effects. This requires an accurate understanding of the mechanism of COPD generation.
- chemokine activates inflammatory cells to produce proinflammatory factors such as TNF- ⁇ , IL-1 ⁇ , IL-6, IL-8, and in particular, inflammatory signals such as NF- ⁇ B and MAPK in TNF- ⁇ . It activates the delivery system, exacerbating the inflammatory response.
- chemokines produce a variety of growth factors and reactive oxygen species that cause persistent inflammatory responses, damage to lung parenchyma, and fibrosis in lung tissues, as well as proinflammatory factors (Lo et al., 2013). This series of reactions results in a significant decrease in pulmonary function, the most characteristic of COPD patients.
- chemokine production such as MIP-2 and CXCL-1 is considered to be a very important method in the treatment of COPD. Indeed, many researchers are also working to develop COPD therapeutics that focus on chemokine inhibition (Buenestado et al., 2013).
- Pistacia weinmannifolia J. Poiss is a plant native to Yunnan province, China, and has been used for headaches including dysentery, enteritis, and flu.
- Previous studies have reported the ability of two compounds isolated from this plant to remove free radicals (Zhao X. et al., Biochim Biophys Acta, 1725, 103-110, 2005).
- the present inventors have diligently tried to find a natural substance useful for treating chronic obstructive pulmonary disease without causing adverse effects on the human body.
- the pistasia Wayne Manifolia extract, its fractions or the compounds isolated therefrom are not toxic.
- the neutrophils were inhibited, CD4 + and Neutrophils Gr-1 + cells in bronchoalveolar lavage fluid were reduced, and the production of CXCL-1 was suppressed.
- the inventors have found that the pistasia Wayne Manifolia extract, fractions thereof, or compounds isolated therefrom have a chronic effect by reducing the amount of inflammatory cells and TNF- ⁇ in bronchoalveolar lavage fluid and reducing MIP-2. It was confirmed that the present invention can be usefully used for the prevention or treatment of obstructive pulmonary disease and completed the present invention.
- One object of the present invention is to provide a pharmaceutical composition for preventing or treating chronic obstructive pulmonary disease, comprising as an active ingredient Pistacia weinmannifolia extract, fractions thereof or compounds isolated therefrom.
- Another object of the present invention is to provide a food composition for preventing or ameliorating chronic obstructive pulmonary disease, which comprises as an active ingredient a pistasia Wayne Manifolia extract, a fraction thereof or a compound separated therefrom.
- Still another object of the present invention is to provide a method for preventing or treating chronic obstructive pulmonary disease, comprising administering the pharmaceutical composition to a subject having or having chronic obstructive pulmonary disease. .
- composition comprising the pistasia Wayne Manifolia extract of the present invention, a fraction thereof or a compound isolated therefrom is not toxic and not only inhibits endobronchial inflammatory cell infiltration in animal models of chronic obstructive pulmonary disease, but also CXCL- 1, the effect of inhibiting the expression of TNF- ⁇ or MIP-2 was excellent.
- plant herbals that have proven safety, they have the advantage of eliminating various side effects of existing treatments for COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic inflammation, preventing chronic obstructive pulmonary disease. It can be usefully used as a composition for treatment and improvement.
- 1 is a diagram showing the separation of the effective fraction using methanol / water solvent for the extract of pistia Wayne Manifolia.
- Figure 2 is a diagram showing the results of UPLC-PDA-QTOF-MS analysis of the effective fraction of ethyl acetate of pistia Wayne Manifolia.
- Figure 3a is a diagram showing the results of UPLC-PDA-QTOF-MS analysis of the compound Pistalcone (PW12) isolated from the effective fraction of pistia Wayne Manifolia.
- Figure 3b is a diagram showing the results of UPLC-PDA-QTOF-MS analysis for the compound Pistalcon B (PW13) isolated from the effective fraction of pistia Wayne Manifolia.
- Figure 4a is prepared from methanol extract, hexane fraction, chloroform fraction, ethyl acetate fraction, butanol fraction and water fraction of Pistacia Wayne Manifolia, and from the ethyl acetate effective fraction, the novel compound pistakalcon (PW12) and compound pistakalcon It is a schematic diagram illustrating the process of separating B (PW13).
- Figure 4b is a diagram showing the results of the fraction analysis to fractionate from the effective fraction with acetonitrile / water solvent to obtain the novel compounds Pistalcon (PW12) and Pistalcon B (PW13) at a wavelength of UV 254, 280 mm.
- PW12 Pistalcon
- PW13 Pistalcon B isolated from the effective fractions 1 to 6 of Pistacia Wayne Manifolia.
- Figure 6 is a diagram confirming the cytotoxicity of the Pistalcon (PW12) and Pistalcon B (PW13) isolated from the extract and the effective fraction 5 of pistia Wayne Manifolia.
- FIG. 7 is a diagram showing the results of measuring the inhibition rate of MUC5AC production induced by TNF- ⁇ of pistachia Wainmanifolia extract, effective fraction 5, and the compounds Pistalcone (PW12) and Pistalcone B (PW13). to be.
- the control group not treated with TNF- ⁇ (-) and the control group treated with TNF- ⁇ (+) were identified as comparison groups.
- the present invention is a Pistacia Wayne Manifolia ( Pistacia) Weinmannifolia ) provides a pharmaceutical composition for preventing or treating Chronic Obstructive Pulmonary Disease (COPD) comprising an extract, a fraction thereof or a compound separated therefrom as an active ingredient.
- COPD Chronic Obstructive Pulmonary Disease
- the compound of the present invention may include a compound represented by the following formula (1) or (2).
- the pharmaceutical composition of the present invention may further comprise a pharmaceutically acceptable carrier.
- Chronic Obstructive Pulmonary Disease differs from asthma in that it is accompanied by irreversible airway obstruction and is caused by pathological changes in bronchioles and pulmonary parenchyma by airway and pulmonary parenchymal inflammation. And emphysema (pulmonary parenchymal destruction).
- Types of chronic obstructive pulmonary disease include chronic obstructive bronchitis, chronic bronchiolitis and emphysema.
- the disease of interest of the composition of the present invention may preferably be a chronic obstructive pulmonary disease, but is accompanied by irreversible airway obstruction to which the present invention is applicable and caused by pathological changes of bronchioles and lung parenchyma by airway and lung parenchymal inflammation. It is not limited to the disease.
- the pistasia Wayne Manifolia extract, fractions thereof or compounds isolated therefrom are used to prevent or treat chronic obstructive pulmonary disease.
- the term "pistia wayne manifolia extract” is obtained by extracting extracts obtained by using a suitable solvent from the roots, leaves, stems, etc. of pistia wayne manifolia, diluents or concentrates of the extracts, and drying the extracts. In the form of dry matter, or a modifier or tablet thereof.
- the pistasia Wayne Manifolia extract may be extracted from various organs of natural, hybrid, and mutant plants, and in particular, may be an extract obtained from the stem of pistia Wayne Manifolia, but is not limited thereto.
- Pistasia Wayne Manifolia extract of the present invention can be prepared using conventional extraction methods, such as ultrasonic extraction, filtration and reflux extraction, pistia Wayne Manifolia can be used to buy a commercially available or It may be used for harvesting or cultivation in nature.
- the pistacia wainmanifolia extract according to the present invention can be separated according to conventional methods known in the art for preparing extracts from natural products, i.e. using conventional solvents under the conditions of conventional temperature, pressure.
- Water, C1-C4 alcohols (anhydrous or hydrous lower alcohols), or a mixed solvent thereof may be used in the preparation of the pistasia Wayne Manifolia extract according to the present invention, but is not limited thereto.
- methanol can be used to prepare the pistasia Wayne Manifolia extract, in particular 70 to 95% methanol can be used as the extraction solvent.
- extraction with a solvent may be performed by heating extraction, cold extraction, reflux cooling extraction, or ultrasonic extraction. Such extraction may be carried out at room temperature or under low temperature or warming conditions.
- the extract is filtered and / or concentrated under reduced pressure to obtain a pistasia Weinmanifolia extract, which may be repeated two or three times, and further subjected to filtration, concentration, lyophilization and the like. have.
- the stems of the collected pistacia wainmanifolia are dried and then ground.
- Methanol was added to the ground powder sample in a volume of 20 times based on its dry weight, and 70 to 95% of methanol extract was obtained at room temperature. Subsequent to filtration and concentration under reduced pressure, a pistasia Wayne Manifolia methanol extract was obtained.
- the term "fraction” means the result obtained by the fractionation method of separating a specific component or a specific group from a mixture comprising various components. In the present invention, it means a result obtained by the fractionation method for separating a specific component or a specific group from the pistcia Wayne Manifolia extract prepared as described above.
- polar solvents such as C1-C4 anhydrous or hydrous lower alcohols, such as water, ethanol, methanol, and hexane
- Non-polar solvents such as butanol, ethyl acetate, chloroform, dichloromethane, or a mixed solvent thereof may be used, but are not limited thereto.
- the pistasia Wayne Manifolia fraction of the present invention may include those obtained by further applying the purification process.
- Fractions obtained through various purification methods additionally carried out by separation by, etc. are also included in the pistasia Wayne Manifolia fraction of the present invention.
- distilled water was added to the methanol extract of the pistasia Wayne Manifolia obtained above, suspended, and the same amount of hexane was added to separate the hexane layer and the water layer. This was repeated three times, followed by filtration and concentration under reduced pressure to obtain a hexane fraction. Then, the hexane fraction was removed, and the same amount of chloroform was added to the remaining water layer to obtain the chloroform fraction in the same manner, and ethyl acetate was added to the remaining water layer to obtain the ethyl acetate fraction in the same manner. The same amount of butanol was added to the remaining water layer to obtain a butanol fraction in the same manner.
- the methanol extract of Pistasia Wayne Manifolia is loaded and the elution rate is 9 ml / min using methanol / water [0: 100-> 100: 0 (v / v)] as a solvent. Fractions were obtained. This gave active fractions 1-7.
- the pistasia Wayne Manifolia extract or fractions thereof may include a compound represented by the following formula (1) or 2 as a representative active ingredient.
- three novel effective compounds that inhibit the inflammatory response of chronic obstructive pulmonary disease were isolated from the pistasia Wayne Manifolia extract or fractions thereof. Specifically, a small fraction of the pistasia Wayne Manifolia effective fraction 5 was re-extracted with methanol / water [10: 90-> 100: 0 (v / v)] as a solvent at an elution rate of 14 ml / min. The new compound PW12 represented by the formula (1) and the new compound PW13 represented by the formula (2) were separated from the small fraction.
- COPD chronic obstructive pulmonary disease
- the compound of formula 1 (PW12) is represented by 2 ', 4'3'',2''', 4 '''-pentahydride as IUPAC by the formula C 30 H 22 O 8 Hydroxy-4-O-3 ''-bicalcone (2 ', 4'3'',2''', 4 '''-pentahydroxy-4-O-3''-bichalcone) It was named Pistakalcon.
- Compound (PW13) is represented by the formula C 45 H 34 O 12 with the name IUPAC di- (2,4-dihydroxybenzoyl)-(3,4-dihydroxyphenyl)-(4-hydroxyphenyl) -Cyclobutane-3-O-4'-bicalcone (di- (2,4-dihydroxybenzoyl)-(3,4-dihydroxyphenyl)-(4-hydroxyphenyl) -cyclobutane-3-O-4'-bichalcone) , We named it Pistalkalcon B.
- Cytokines such as TNF- ⁇ and CXC chemokines such as MIP-2 are known to be involved in the trafficking activity of neutrophils from pulmonary vascular circulation to alveoli. These are all cytokines or chemokines associated with inflammation, in the case of chronic obstructive pulmonary disease, the number of neutrophils is increased and the cytokines or chemokines are secreted. This causes inflammation of the airways, thickening of the muscle walls, increased mucus secretion and bronchial obstruction. When the bronchus is closed, the alveoli expand and become damaged, impairing the exchange capacity of oxygen and carbon dioxide, and increasing respiratory failure. In particular, these cytokines or chemokines have been shown to have increased expression in patients suffering from COPD, which has been associated with chronic obstructive pulmonary disease.
- chronic obstructive pulmonary disease response can be suppressed by inhibiting the secretion of proteins selected from the group consisting of CXCL-1, TNF- ⁇ and MIP-2.
- CD4 + cells are known as cells that promote immunity, and autoimmunity may occur when the cells increase excessively.
- the number of CD4 + cells is known to be significantly higher than that of normal individuals (Proceedings of the American Thoracic Society, Vol. 4, No. 7 (2007), pp. 512-521.).
- the pistasia Wayne Manifolia extract of the present invention may exhibit the following activities.
- the methanol extract of pistia Wayne Manifolia according to the present invention is inhaled standard tobacco extract
- the number of neutrophils was significantly suppressed (see Table 5), CD4 + and Neutrophils Gr-1 + cell numbers (see Table 6), CXCL-1 (see Table 7), TNF- ⁇ (see Table 8), MIP It was found to decrease -2 (see Table 9).
- the pistasia Wayne Manifolia extract and fractions thereof of the present invention can be usefully used for the prevention and treatment of COPD.
- the present invention provides a composition for the prevention or treatment of COPD comprising a pistasia Weinmanifolia extract, a fraction thereof or a compound thereof as an active ingredient and a pharmaceutically acceptable carrier.
- the COPD may be selected from the group consisting of multiple sclerosis, acute and chronic inflammation, such as chronic obstructive bronchitis, chronic bronchiolitis and emphysema, preferably chronic obstructive pulmonary disease.
- multiple sclerosis, acute and chronic lung diseases to which the present invention is applicable are not limited thereto.
- chronic obstructive pulmonary disease refers to a respiratory disease in which abnormal inflammatory reactions occur in the lungs by inhalation of harmful particles or gases, thereby gradually limiting air flow, thereby lowering lung function and causing respiratory distress.
- the main symptoms of chronic obstructive pulmonary disease include chronic cough or chronic sputum (sputum), shortness of breath, and beta-inhibitors, anticholinergic agents, bronchodilators such as methylxanthine, or corticosteroid inhalation. do.
- the chronic obstructive pulmonary disease may preferably be chronic bronchitis or emphysema, but is not limited thereto.
- chronic bronchitis refers to a disease in which there is more than 3 months of sputum and cough persists for two consecutive years. Bronchial damage caused by stimulation such as smoking, air pollution, occupational exposure, etc. is presumed to be the cause, and the main symptoms include chronic cough, sputum, and difficulty breathing during exercise. In addition, there may be an acute exacerbation that is a hallmark of chronic obstructive pulmonary disease, when breathing difficulties rapidly deteriorate for hours to days and the amount of sputum increases or the appearance of sputum changes from mucus to purulent, dark yellow or bluish. The color becomes high and the viscosity increases, making it hard to spit out.
- the term “emphysema” refers to an abnormal and permanent expansion of the peripheral airways and alveoli due to destruction of the terminal bronchiole distal airspace. Caused by inhalation of harmful particles and gases, the most clinically significant risk factor is known as smoking. The main symptoms include chronic cough, sputum and dyspnea.
- prevention refers to any action that inhibits or delays the development of multiple sclerosis, acute and chronic lung disease, including chronic obstructive pulmonary disease, by administration of a composition according to the present invention.
- treatment refers to any action that inhibits or delays the development of multiple sclerosis, acute and chronic lung disease, including chronic obstructive pulmonary disease, by administration of a composition according to the present invention.
- pharmaceutically acceptable is meant that it does not significantly irritate the organism and does not inhibit the biological activity and properties of the administered active substance.
- the pharmaceutical composition of the present invention comprising a pharmaceutically acceptable carrier may be in various oral or parenteral formulations.
- diluents or excipients such as fillers, extenders, binders, wetting agents, disintegrating agents, and surfactants are usually used.
- Solid form preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, which form at least one excipient such as starch, calcium carbonate, sucrose or lactose ( lactose) and gelatin.
- lubricants such as magnesium stearate, talc and the like are also used.
- Liquid preparations for oral administration include suspensions, solutions, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. have.
- Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories.
- non-aqueous solvent and the suspension solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
- As the base of the suppository witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
- the pharmaceutical composition is any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, liquid solutions, emulsions, syrups, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations and suppositories. It can have one formulation.
- compositions of the present invention may comprise a pharmaceutically effective amount of pistasia Wayne Manifolia extract, fractions thereof or compounds isolated therefrom.
- pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level is the type of subject and its severity, age, sex, activity of the drug. , Sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrent use of the drug, and other factors well known in the medical arts.
- the pharmaceutical compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
- the pharmaceutical composition according to the present invention may be included in the pharmaceutical composition is 0.001 to 1500 ⁇ g / ml, more preferably 0.001 to 1000, Pistcia Weinmanifolia extract, fractions or compounds separated therefrom May be included in ⁇ g / ml.
- the composition according to the present invention may include 1 to 10% by weight of pistasia Wayne Manifolia extract or a fraction thereof, and particularly may include 5 to 10% by weight.
- the pharmaceutical composition according to the present invention may be one containing from 0.01 to 10% by weight of a compound, for example, a compound represented by formula (1) or (2), which is separated from the pistasia Wayne Manifolia.
- the present invention provides a method for preventing or treating COPD by administering to a subject in need of preventing or treating COPD, a pharmaceutical composition comprising a pistasia Wayne Manifolia extract, a fraction thereof, or a compound isolated therefrom do.
- the pistasia Wayne Manifolia extract, fractions thereof, or compounds separated therefrom are as described above.
- the COPD may be selected from the group consisting of chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic inflammation, preferably may be COPD, chronic obstructive bronchitis, chronic bronchiolitis, emphysema, Multiple sclerosis, acute and chronic inflammatory diseases are not limited thereby.
- the subject means all animals, including humans, who may or may develop chronic obstructive pulmonary disease, and suspect the chronic obstructive pulmonary disease of the pharmaceutical composition comprising the compound of the present invention or a pharmaceutically acceptable salt thereof.
- the individual can be treated efficiently.
- the subject is an individual in need of prevention or treatment of COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung diseases, etc. , Sheep, pigs, goats, camels, antelope, dogs, cats, and other mammals, but is not limited thereto.
- the term "administration" refers to introducing the pharmaceutical composition of the present invention to a patient in any suitable manner, the route of administration of the composition of the present invention being oral or parenteral as long as it can reach the target tissue. Administration can be via a variety of routes.
- the method of treatment of COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung disease of the present invention is administered in a pharmaceutically effective amount of pistasia Wayne Manifolia extract, fractions thereof or a compound isolated therefrom It involves doing. That is, the method of treating COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung diseases of the present invention comprises a pistasia Wayne Manifolia extract, a fraction thereof or a compound isolated therefrom Administering the pharmaceutical composition in a pharmaceutically effective amount.
- the term “pharmaceutically effective amount” means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and an effective dose level is determined by the type and severity, age, sex, disease of the individual. It may be determined according to the type, activity of the drug, sensitivity to the drug, time of administration, route of administration and rate of release, duration of treatment, factors including concurrently used drugs, and other factors well known in the medical field.
- the compositions of the present invention may be administered as individual therapeutic agents or in combination with other therapeutic agents and may be administered sequentially or simultaneously with conventional therapeutic agents. And single or multiple administrations.
- the preferred dosage of the composition of the present invention depends on the condition and weight of the patient, the extent of the disease, the form of the drug, the route of administration and the duration of time, and the suitable total daily dosage can be determined by the practitioner within the correct medical judgment. Generally, an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, may be administered once to several times daily.
- the composition is not particularly limited as long as it is an individual for the purpose of preventing or treating chronic obstructive pulmonary disease, and any individual may be applied.
- any individual such as non-human animals such as monkeys, dogs, cats, rabbits, marmots, rats, mice, cows, sheep, pigs, goats, humans, birds, and fish
- Any conventional method may be used without limitation.
- it may be administered by oral, rectal or intravenous, intramuscular, subcutaneous, intrauterine dural or cerebrovascular injections.
- the present invention provides the use of a pistasia Wayne Manifolia extract, a fraction thereof or a compound isolated therefrom for the prevention or treatment of chronic obstructive pulmonary disease.
- the present invention provides a food composition for the prevention or amelioration of chronic obstructive pulmonary disease comprising a pistasia Wayne Manifolia extract, a fraction thereof or a compound isolated therefrom.
- the food composition of the present invention may further comprise a food acceptable carrier.
- the pistasia Wayne Manifolia extract, fractions thereof, or compounds isolated therefrom and chronic obstructive pulmonary disease are as described above.
- the food composition may have a function of helping to suppress COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute or chronic lung disease.
- the food composition of the present invention includes the form of pills, powders, granules, acupuncture, tablets, capsules or liquids, etc., and can be added to the pistasia Wayne Manifolia extract of the present invention, fractions thereof, or a compound separated therefrom.
- a compound separated therefrom There is no restriction
- the food composition in addition to the pistasia Wayne Manifolia extract, fractions or compounds isolated therefrom may be added to other components that do not interfere with chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung disease inhibitory activity And the kind is not particularly limited.
- various herbal extracts, food acceptable additives, natural carbohydrates, and the like may be contained as additional ingredients, such as conventional foods.
- the term "food supplement” refers to a component that can be added to food supplements, and can be appropriately selected and used by those skilled in the art as being added to prepare a health functional food of each formulation.
- food additives include flavors such as various nutrients, vitamins, minerals (electrolytes), synthetic and natural flavors, colorants and fillers, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners. , pH regulators, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated beverages, and the like, but is not limited to the kind of food additives of the present invention by the above examples.
- Examples of the natural carbohydrate include monosaccharides such as glucose and fructose; Disaccharides such as maltose and sucrose; And sugars such as polysaccharides such as dextrin and cyclodextrin, and xylitol, sorbitol, and erythritol.
- natural flavoring agents tauumatin, stevia extract (e.g., Rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be advantageously used. .
- the food composition of the present invention may include a health functional food.
- the term "health functional food” refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body.
- functional means to obtain a useful effect for health use such as nutrient control or physiological action on the structure and function of the human body.
- the health functional food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding raw materials and ingredients commonly added in the art.
- unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug with food as a raw material, can be excellent in portability.
- the composition of the present invention When the composition of the present invention is used in a health functional food, the composition may be added as it is or used with other health functional foods or health functional food ingredients, and may be appropriately used according to a conventional method.
- the mixed amount of the active ingredient may be appropriately determined depending on the purpose of use (prevention, health or therapeutic treatment).
- the pistasia Wayne Manifolia extract or fractions thereof of the present invention is added in an amount of 1 to 10% by weight, preferably 5 to 10% by weight of the raw material composition.
- the amount may be used below the above range.
- Examples of the food to which the substance can be added include dairy products including meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, ice cream, various soups, drinks, tea, drinks, Alcoholic beverages and vitamin complexes, and includes all of the health functional foods in the conventional sense.
- the term "improvement” refers to all the actions that improve or benefit the symptoms of the suspected and the onset of chronic obstructive pulmonary disease using the composition.
- health functional food may include the composition of the present invention
- specific examples include meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gums, and ice cream.
- Dairy products, various soups, beverages, tea, drinks, alcoholic beverages and vitamin complexes, etc. may include all of the health functional foods in the conventional sense, and may include foods used as feed for animals.
- the health functional food composition of the present invention when used in the form of a beverage, it may contain various sweetening agents, flavoring agents or natural carbohydrates, etc. as additional ingredients, as in the usual beverage.
- the natural carbohydrate may be glucose, monosaccharides such as fructose, maltose, disaccharides such as sucrose, polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, erythritol.
- the ratio of the natural carbohydrate is not limited thereto, but may be preferably about 0.01 to 0.04 g, more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention.
- the sweetener may be a natural sweetener such as taumartin, stevia extract and a synthetic sweetener such as saccharin, aspartame.
- the nutraceutical composition of the present invention includes various nutrients, vitamins, electrolytes, flavors, coloring agents, pectic acid and salts thereof, alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH regulators, stabilizers, preservatives, glycerin , Alcohols, carbonating agents used in carbonated drinks, and the like. Others may contain pulp for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
- the present invention provides a compound represented by the formula (1) or formula (2) isolated from pistacia Wayne Manifolia, extracts thereof or fractions thereof.
- two novel effective compounds that inhibit the inflammatory response of chronic obstructive pulmonary disease were isolated from the pistasia Wayne Manifolia extract or fractions thereof.
- COPD chronic obstructive pulmonary disease
- a small fraction of the pistasia Wayne Manifolia effective fraction 5 was re-extracted with methanol / water [10: 90-> 100: 0 (v / v)] as a solvent at an elution rate of 14 ml / min.
- the new compound PW12 represented by the formula (1) and the new compound PW13 represented by the formula (2) were separated from the small fraction.
- Example 1-1 To 542.2 g of the total extract of pistasia Wayne Manifolia obtained in Example 1-1, 5 L of water was added and suspended. The same amount of hexane was added to separate the water layer and the hexane layer. This process was repeated three more times in the same manner, filtered and concentrated under reduced pressure to separate the hexane fraction (48.5 g). The hexane layer was separated in the same manner, and the same amount of chloroform was added to the remaining water layer to separate in the same manner to obtain a chloroform fraction (16.3 g).
- the chloroform layer was separated in the same manner, and the same amount of ethyl acetate was added to the remaining water layer, and the mixture was separated in the same manner to obtain an ethyl acetate fraction (53.7 g).
- the ethyl acetate layer was separated in the same manner, but the same amount of butanol was added to the remaining water layer, and the mixture was separated in the same manner to obtain a butanol fraction (114 g).
- the remaining water layer was concentrated to give a water fraction (186.5 g).
- the MPLC instrument (Interchim) was equipped with a column (20 mm ⁇ 250 mm; Resin; Zeoprep C18, 10 ⁇ m) for MPLC analysis, and the methanol extract was repeatedly loaded in an amount of 2 g.
- methanol / water [0: 100-> 100: 0 (v / v)] was used as the solvent, the elution rate was 9 ml / min, and the active fraction (Fr) was detected at a wavelength of UV 200-400 mm. .1 to 7) were obtained.
- the analysis time was 120 minutes for the ethyl acetate fraction.
- ethyl acetate fraction (53.7 g) was filtered once with a 0.25 mm membrane filter for UPLC for UPLC analysis.
- a column (Waters BEH C18 column, 2.1 ⁇ 100 mm, 1.7 mm) was mounted on a UPLC instrument (Waters UPLC-Q-TOF), and each filtered fraction was loaded in an amount of 0.3 ⁇ l.
- the effective fraction Fr.5 (821 mg) was loaded on the MPLC instrument (YMC Lc-Forte / R) with a column (YMC-DispoPack AT, 40 ⁇ 500 mm, 45 ⁇ m) and then loaded with the active fraction.
- methanol / water 10:90-> 100: 0 (v / v)] was used as the solvent, and the elution rate was 14 ml / min.
- the fraction was detected at a wavelength of UV 254, 280, and 320 mm. (Fr. 5A-G) was obtained.
- the small fraction Fr.5F (156 mg) Prep-HPLC instrument (Gilson) was equipped with a column (YMC-Pack ODS AQ-HG, 250 x 20 mm, 5 ⁇ m) and then the effective fractions were added in an amount of 10 mf / ml. Loaded. In this case, acetonitrile / water [10:90-> 100: 0 (v / v)] was used as the solvent, the elution rate was 14 ml / min, and the following physical properties were performed at a wavelength of UV 254, 280 mm. To obtain a compound PW12 (20.5 mg) of the novel structure represented by the formula (2) (Table 2 and Figure 4b).
- H292 (CRL-1848) was purchased from American Type Culture Collection (ATCC). H292 cells were cultured in RPMI medium (SH30027.01, RPMI 1640, Gibco) to which 10% fetal bovine serum and antibiotics were added, and cultured at 37 ° C. under humidified 5% CO 2 atmospheric conditions. TNF- ⁇ was purchased from a company (300-01A, Peprotech, USA) and used.
- the cells were placed in density (1 ⁇ 10 3 cells / well) in 96-well plates in medium (GM). After 24 hours, cells were incubated with the sample for 1 day. Cell viability was read in triplicate using a reading kit (Cell Counting Kit-8, CK04-01, Dojindo Molecular Technologies, ML) according to the manufacturer's manual. Absorbance was measured using a reader (VERSAmax microplate reader, SMP500-14915, Molecular Devices, USA) and the measured absorbance was converted to cell number in a standard curve.
- H292 cells which are human lung cancer mucosal cells, were suspended in RPMI medium (Gibco) containing 10% Fetal Bovine Serum at a concentration of 5 x 10 4 cells / ml and inoculated into 96 well-plates at 100 ⁇ l. Attached for 12 hours. Pistasia effective fraction 6 and three single compounds (PW11, PW12, PW13) were treated by concentration, and then cultured for 24 hours. As described in the CCK-8 (Dojindo Co., Ltd.) kit for counting cell numbers, 10 ⁇ l of CCK-8 solution was added to 90 ⁇ l of medium, and 100 ⁇ l was added per well, followed by reaction for at least 30 minutes up to 4 hours. Absorbance was measured at 570 nm. Cell viability was calculated according to Equation 1 with a 0.2% DMSO-treated negative control group, and the results are shown in Table 3 below.
- mice Male BALB / c male mice with an average body weight of about 20 g were used as experimental animals. Animals were examined in which no abnormalities were observed on basic physical examination after one week of adaptation.
- Cigarette 7 (Coresta Monitering Cigarette 7, Heinr Borgwaldt, Germany) smoke condensate was carried out in a smoking room (temperature 22 ⁇ 2 °C, relative humidity 60 ⁇ 5%) in accordance with ISO3402.
- Cigarette cigarettes were burned by the ISO standard smoking method and tobacco smoke condensates were collected with a 92 mm cambridge filter (ISO 3308 standard) (ISO 3308, 2000).
- Tobacco smoke condensate collected camberidge filter was separated from the cigaratte holder and put into 100 mL Erlenmeyer flask, each 50 mL of extraction solvent isopropanol was added, shaken well, and left at room temperature for 8 hours or more. After extraction, the resultant was filtered, concentrated with a vacuum filtration concentrator, and the concentrates contained in three Erlenmeyer flasks were collected in a scintillation vial and completely concentrated using nitrogen gas. After anesthesia with 7% chloral hydrate, add 100 ⁇ l of LPS + CS (100 ⁇ g / ml of LPS and 4 mg / ml of Cigarette smoking (CS) 1: 1) once a week for 3 weeks.
- Inhalation produced a model of chronic obstructive pulmonary disease. Specifically, 100 ⁇ l of a total of 50 ⁇ l of the LPS + CS mixture in the nose and mouth were inhaled i.t while the anterior teeth of the mouse were fixed with a rubber band when there was no movement after weak anesthesia.
- the experimental group was treated with (i) no treatment (NC), (ii) control group treated with LPS + CS (COPD), and (iii) P. weinmanifolia 30 mg / kg 1 hour prior to treatment with LPS + CS.
- the experimental group was administered ( P. weinmanifolia ). After the experiment, blood, lung wash solution and lung tissue of each group of mice were separated.
- TPM is the total particulate matter
- W FHA is the weight of the filter holder after smoking
- W FHB is the weight of the filter holder before smoking
- N is the number of cigarettes smoked per trap.
- mice In order to measure bronchial alveolar lavage secretion and total cell number of pistasia Wayne Manifolia extract, the bronchial tubes of mice were treated with ACK solution at 37 ° C. for 5 minutes to dissolve red blood cells and washed with FBS-free / DMEM medium. Total cell number was measured after staining with 0.04% trypan blue.
- a syringe containing 1 ml of FBS-free / DMEM medium was injected into the bronchus (trachea).
- 8.3 g NH4Cl, 1 g KHCO3 in 1 L demineralized water + 0.1 mM EDTA) solution was treated at 37 ° C. for 5 minutes to dissolve erythrocytes, washed with FBS-free / DMEM medium, and then 0.04% trypan blue After staining with the total cell number was measured.
- the total methanol extract obtained in Preparation Example 1 was used as a sample.
- Table 5 shows the results of measuring the effect of methanol extract (Total) of pistacia Wayne Manifolia on the production of neutrophils in the total number of inflammatory cells in bronchoalveolar lavage fluid in COPD animal models induced by standard tobacco extract.
- NC normal control group without airway sensitization
- COPD induction COPD induction group induced with standard tobacco extract
- BAL cells isolated in Example 5 were adjusted 5 ⁇ 10 5 cells and then subjected to immunogluorescence staining at 4 ° C.
- PE-anti-CD4 (553047, BD Pharmingen)
- PE-anti-Gr-1 553128, BD Pharmingen
- the cells were washed with phosphate buffered saline three times or more, and then analyzed by the flow cytometer Cell Quest program (643274, BD Pharmingen) for analyzing the frequency of CD4 + and Gr-1 + Neutrophil cells in percentage (%). Total cells were used to calculate the absolute total number of cells in each tissue.
- Table 6 shows the results of measuring the effect of methanol extract of pistasia Wayne Manifolia on CD4 + and Neutrophils Gr-1 + cell numbers in bronchoalveolar lavage fluid in COPD-induced animal models.
- NC normal control group without airway sensitization
- COPD induction COPD induction group induced with standard tobacco extract
- the COPD induction group significantly increased both the number of CD4 + and Neutrophils Gr-1 + cells compared to the normal control.
- 30 mg / kg of P.Weinmannifolia the drug-administered group, showed a 70.3% (P ⁇ 0.05) increase in CD + cell count and 86.7% (P ⁇ 0.05) in comparison with COPD induction group. Suppressed.
- CXCL-1, TNF- ⁇ and MCP-2 levels in BALF isolated from mice were measured by an enzyme-linked immuno-sorbent assay (ELISA).
- ELISA enzyme-linked immuno-sorbent assay
- Each antibody of CXCL-1, TNF- ⁇ and MCP-2 was diluted in coating buffer solution (291195, R & D System), coated on microwell and overnight at 4 ° C. Each well was washed three times with buffer, and then 100 ⁇ l of serum (10-fold dilution) was dispensed. After standing at room temperature for 1 hour, washed twice with washing buffer, and then treated with 100 ⁇ l of antibody Avidin-HRP conjugeted (DY998, R & D System), and washed again at room temperature for 1 hour. TMB substrate was dispensed by 100 ⁇ l, left in the dark for 30 minutes, treated with 50 ⁇ l of stop solution, and absorbance was measured at 450 nm of ELISA leader (Emax, Molecular Devices).
- Table 7 shows the results of measuring the effect of methanol extract of pistasia Wayne Manifolia on the production of CXCL-1 in bronchoalveolar lavage fluid in a COPD-induced animal model.
- NC normal control group without airway sensitization
- COPD induction COPD induction group induced with standard tobacco extract
- the COPD induction group significantly increased the production of CSCL-1 in bronchoalveolar lavage fluid compared to the normal control group.
- P. Weinmannifolia 30 mg / kg administration group was 67.0% (P ⁇ 0.05) inhibited the production of CXCL-1 compared to the COPD-induced group.
- Table 8 is a result of measuring the effect of methanol extract of pistia weinmanifolia on TNF-a, an inflammatory factor in a COPD-induced animal model.
- NC normal control group without airway sensitization
- COPD induction COPD induction group induced with standard tobacco extract
- Table 8 group TNF- ⁇ (pg / mL) Inhibition Rate (%) NC 1.5 ⁇ 0.34 - COPD induction 35.0 ⁇ 9.68 - COPD Induction after P.weinmannifolia Extract Treatment 13.0 ⁇ 3.50 62.8
- the COPD induction group significantly increased the production of TNF- ⁇ in the bronchoalveolar lavage fluid compared with the normal control group.
- P. Weinmannifolia 30 mg / kg administration group was 62.8% (P ⁇ 0.05) inhibited TNF- ⁇ production compared to the COPD-induced group.
- Table 9 is a result of observing the effect of methanol extract of pistia Wayne Manifolia on the production of MCP-2 in bronchoalveolar lavage fluid in a COPD-induced animal model.
- NC normal control group without airway sensitization
- COPD induction COPD induction group induced with standard tobacco extract
- the COPD induction group significantly increased the production of TMCP-2 in bronchoalveolar lavage fluid compared to the normal control group.
- P. Weinmannifolia 30 mg / kg administration group was 62.8% (P ⁇ 0.05) inhibited the production of MCP-2 compared to the COPD-induced group.
- the pistasia Wayne Manifolia extract of the present invention is generally non-cytotoxic at concentrations that induce a prophylactic or therapeutic effect of COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung disease. Confirmed.
- the pistasia Wayne Manifolia extract of the present invention is a natural material useful for the treatment of chronic obstructive pulmonary disease without causing adverse effects on the human body, COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic It can be used safely in pharmaceutical compositions, food compositions and functional feed for preventing, ameliorating or treating lung diseases.
- the pistasia Wayne Manifolia extract according to the present invention has high COPD and chronic obstructive bronchitis, chronic bronchiolitis, emphysema, multiple sclerosis, acute and chronic lung disease.
- compositions comprising the pistasia Wayne Manifolia extract or fractions of the present invention were prepared according to conventional methods as follows.
- tablets were prepared by tableting according to a conventional method for preparing tablets.
- the capsule was prepared by filling in gelatin capsules according to the conventional method for producing a capsule.
- Pistasia Wayne Manifolia extract prepared in Examples 1-1, 1-2, and 1-3, fractions 0.5 to 5.0% by weight or compounds Pistalcone (PW12) or Pistalcone B (PW13) 0.01 To 10% by weight was added to the flour, using this mixture to prepare bread, cakes, cookies, crackers and noodles to prepare foods for the prevention or improvement of chronic obstructive pulmonary disease.
- Pistasia Wayne Manifolia extract prepared in Examples 1-1, 1-2 and 1-3, fractions 5 to 10.0% by weight or compounds Pistalcone (PW12) or Pistalcone B (PW13) 0.01 To 10% by weight was added to the milk, using the milk to prepare a variety of dairy products such as butter and ice cream.
- Brown rice, barley, glutinous rice, and yulmu were alphad by a known method, and then dried and roasted to prepare a powder having a particle size of 60 mesh.
- Black beans, black sesame seeds, and perilla were also steamed and dried by a known method, and then ground to a powder having a particle size of 60 mesh.
- the pistasia Wayne Manifolia extract prepared in Examples 1-1, 1-2, and 1-3, fractions thereof, or a compound solution separated therefrom was concentrated under reduced pressure in a vacuum concentrator, dried by spraying, and hot air dryer. The obtained dried product was ground to a particle size of 60 mesh to obtain a dry powder.
- the grains, seeds, and pistasia Wayne Manifolia extract, fractions thereof, or dry powders of the compounds prepared therefrom were prepared by combining the above-mentioned powders in the following ratios.
- Seeds (7% by weight perilla, 8% by weight black beans, 7% by weight black sesame seeds),
- the resulting solution is filtered and obtained in a sterilized 2 L container, sealed sterilization and refrigerated Used to prepare the healthy beverage composition of the invention.
- composition ratio is a composition suitable for a preferred beverage in a preferred embodiment
- the composition ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and intended use.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Nutrition Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Physiology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
분획물 | 용매조건 | 번호(bottle number) | 무게(mg) | |
Fr.1 | 분획물 1 | 0-26 | 1-12 | 32.1 |
Fr.2 | 분획물 2 | 26-40 | 13-18 | 253.7 |
Fr.3 | 분획물 3 | 40-53 | 19-24 | 400.2 |
Fr.4 | 분획물 4 | 53-65 | 25-29 | 85.9 |
Fr.5 | 분획물 5 | 65-100 | 30-45 | 65.3 |
Fr.6 | 분획물 6 | 100 | 46-60 | 27.5 |
구분 | 데이터 |
PW12(화학식 1) | Amorphous powder; HRESIMS m/z 509.1236 [M-H]-; 1H-NMR (400 MHz, MeOD) δ 7.73 (1H, d, J = 8.8 Hz, H-2), 6.98 (1H, d, J = 8.8 Hz, H-3), 6.98 (1H, d, J = 8.8 Hz, H-5), 7.73 (1H, d, J = 8.8 Hz, H-6), 6.28 (1H, d, J = 2.3 Hz, H-3'), 6.40 (1H, dd, J = 8.8, 2.3 Hz, H-5'), 7.94 (1H, d, J = 8.8 Hz, H-6'), 7.64 (1H, d, J = 15.3 Hz, H-α), 7.80 (1H, d, J = 15.3 Hz, H-β), 7.50 (1H, d, J = 2.0 Hz, H-2''), 7.04 (1H, d, J = 8.4 Hz, H-5''), 7.53 (1H, d, J = 8.4, 2.0 Hz, H-6''), 6.28 (1H, d, J = 2.3 Hz, H-3'''), 6.40 (1H, dd, J = 8.8, 2.3 Hz, H-5'''), 7.94 (1H, d, J = 8.8 Hz, H-6'''), 7.64 (1H, d, J = 15.3 Hz, H-α'), 7.80 (1H, d, J = 15.3 Hz, H-β'); 13C-NMR (100 MHz, MeOD) δ. 130.6, 131.6, 117.8, 161.8, 117.8, 131.6, 114.7, 167.6, 103.8, 166.5, 109.2, 193.3, 133.5, 120.2, 144.6, 129.0, 123.4, 144.2, 153.5, 118.8, 128.6, 114.7, 167.5, 103.8, 166.4, 109.2, 133.5, 119.7, 144.7, 193.4 |
PW13(화학식 2) | Amorphous powder; HRESIMS m/z 765.1972 [M-H]-. 1H-NMR (400 MHz, MeOD) δ 6.86 (1H, d, J = 2.0 Hz, H-2), 6.98 (1H, d, J = 8.4 Hz, H-5), 7.15 (1H, dd, J = 8.4, 2.0 Hz, H-6), 3.64 (1H, dd, J = 9.2, 8.8 Hz, H-7), 4.45 (1H, dd, J = 8.8, 7.8 Hz, H-8), 6.19 (1H, d, J = 2.3 Hz, H-12), 6.06 (1H, dd, J = 8.8, 2.3 Hz, H-14), 7.31 (1H, d, J = 8.8 Hz, H-15), 7.64 (2H, d, J = 8.4 Hz, H-2',6'), 6.85 (2H, d, J = 8.4 Hz, H-3',5'), 6.28 (1H, d, J = 2.3 Hz, H-9'), 6.41 (1H, dd, J = 8.8, 2.3 Hz, H-11'), 7.98 (1H, d, J = 8.8 Hz, H-12'), 7.66 (1H, d, J = 15.4 Hz, H-α), 7.79 (1H, d, J = 15.4 Hz, H-β), 7.12 (2H, d, J = 8.4 Hz, H-2'',6''), 6.74 (2H, d, J = 8.4 Hz, H-3'',5''), 3.71 (1H, dd, J = 9.2, 8.8 Hz, H-7''), 4.45 (1H, dd, J = 8.8, 7.8 Hz, H-8''), 6.23 (1H, d, J = 2.3 Hz, H-12''), 6.15 (1H, dd, J = 8.8, 2.3 Hz, H-14''), 7.31 (1H, d, J = 8.8 Hz, H-15''); 13C-NMR (100 MHz, MeOD) δ 134.7, 122.4, 143.8, 149.7, 118.8, 125.6, 150.2, 47.7, 203.2, 113.1, 167.0, 109.1, 167.0, 103.7, 134.3, 130.5, 131.4, 117.9, 161.7, 114.6, 167.4, 109.5, 167.6, 103.9, 133.5, 120.2, 144.7, 193.3, 133.2, 129.6, 116.5, 157.8, 49.6, 47.7, 202.9, 113.1, 167.0, 109.3, 167.0, 103.8, 134.3. |
시료 | 농도 | H292 세포 생존율(%, 평균 ± 편차) |
음성대조군 | 0 | 99.99±3.79 |
피스타시아 웨인마니아폴리아 추출물(μg/mL) | 0.125 | 96.46±1.50 |
0.25 | 91.61±6.12 | |
0.5 | 103.14±1.47 | |
1 | 103.68±2.89 | |
2.5 | 106.45±1.60 | |
5 | 103.84±1.42 | |
피스타시아 웨인마니폴리아분획물 6(μg/mL) | 0.125 | 92.61±1.39 |
0.25 | 96.30±3.57 | |
0.5 | 99.68±2.31 | |
1 | 107.06±6.47 | |
2.5 | 81.93±2.31 | |
5 | 52.72±0.48 | |
화합물 PW11(μM) | 0.125 | 97.60±1.83 |
0.25 | 98.05±0.93 | |
0.5 | 104.65±0.79 | |
1 | 90.24±4.34 | |
화합물 PW12(μM) | 0.125 | 95.80±2.90 |
0.25 | 96.47±3.21 | |
0.5 | 104.50±1.32 | |
1 | 115.88±0.50 | |
화합물 PW13(μM) | 0.125 | 104.80±2.34 |
0.25 | 103.53±3.07 | |
0.5 | 126.28±7.75 | |
1 | 71.92±5.47 |
시료 | 농도(μM) | TNF-α(20 ng/㎖) | MUC5AC 분비량 (TNF-α 처리군에 대한 상대적 %) | 저해율(%) |
음성대조군 | 0 | - | 42.58±1.38 | 57.42 |
TNF-α 처리군 | 0 | + | 100.00±3.24 | 0 |
피스타시아웨인마니폴리아추출물 | 5 | + | 79.93±4.79 | 20.07 |
2.5 | + | 87.35±8.13 | 12.65 | |
1 | + | 92.82±3.90 | 7.18 | |
0.5 | + | 92.34±10.81 | 7.66 | |
0.25 | + | 103.16±4.96 | 0 | |
0.125 | + | 115.21±5.93 | 0 | |
피스타시아 웨인마니폴리아분획물 6 | 5 | + | 56.20±3.24 | 43.80 |
2.5 | + | 69.95±2.35 | 30.05 | |
1 | + | 71.29±3.80 | 28.71 | |
0.5 | + | 76.76±3.75 | 23.24 | |
0.25 | + | 93.43±7.90 | 6.57 | |
0.125 | + | 102.07±7.66 | 0 | |
화합물 PW11 | 1 | + | 76.95±8.13 | 23.05 |
0.5 | + | 79.67±1.14 | 20.33 | |
0.25 | + | 86.64±3.99 | 13.36 | |
0.125 | + | 88.18±9.42 | 11.82 | |
화합물 PW12 | 1 | + | 69.74±8.56 | 30.26 |
0.5 | + | 69.50±5.37 | 30.50 | |
0.25 | + | 74.23±12.98 | 25.77 | |
0.125 | + | 75.77±7.66 | 24.23 | |
화합물 PW13 | 1 | + | 73.76±2.68 | 26.24 |
0.5 | + | 77.30±2.33 | 22.70 | |
0.25 | + | 82.39±3.10 | 17.61 | |
0.125 | + | 83.92±9.77 | 16.08 |
그룹 | 면역 세포 수 | |||
총 세포 | 저해율(%) | 중성구 (Neutrophil) | 저해율 (%) | |
NC | 20.1 ± 4.41 | - | 0.5 ± 0.12 | - |
COPD 유도 | 95.4 ± 16.99 | - | 202.8 ± 24.48 | - |
P.weinmannifolia 추출물 처리 후 COPD 유도 | 28.0 ± 5.50 | 70.6 | 116.8 ± 37.43 | 59.8 |
그룹 | 세포 수 | |||
CD4+ 세포 (104) | 저해율(%) | Neutrophil+Gr-1+(104) | 저해율 (%) | |
NC | 7.5 ± 1.49 | - | 0.4 ± 0.08 | - |
COPD 유도 | 510.1 ± 157.65 | - | 33.9 ± 8.19 | - |
P.weinmannifolia 추출물 처리 후 COPD 유도 | 152.8 ± 66.25 | 70.3 | 4.7 ± 1.14 | 86.2 |
그룹 | CXCL-1 (pg/mL) | 저해율 (%) |
NC | 71.9 ± 15.93 | - |
COPD 유도 | 312.6 ± 63.16 | - |
P.weinmannifolia 추출물 처리 후 COPD 유도 | 103.2 ± 11.06 | 67.0 |
그룹 | TNF-α (pg/mL) | 저해율 (%) |
NC | 1.5 ± 0.34 | - |
COPD 유도 | 35.0 ± 9.68 | - |
P.weinmannifolia 추출물 처리 후 COPD 유도 | 13.0 ± 3.50 | 62.8 |
그룹 | MCP-2 (pg/mL) | 저해율 (%) |
NC | 12.0 ± 1.75 | - |
COPD 유도 | 48.7 ± 15.02 | - |
P.weinmannifolia 추출물 처리 후 COPD 유도 | 17.6 ± 4.07 | 62.8 |
Claims (18)
- 피스타시아 웨인마니폴리아 (Pistacia weinmannifolia) 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 포함하고 만성폐쇄성 폐질환(Chronic Obstructive Pulmonary Disease, COPD) 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 약제학적으로 허용가능한 담체를 추가로 포함하는 만성폐쇄성 폐질환 예방 또는 치료용 약학적 조성물.
- 제1항에 있어서, 상기 추출물은 물, C1 ~ C4의 알코올 또는 이들의 혼합용매를 사용하여 추출된 것인 약학적 조성물.
- 제1항에 있어서, 상기 추출물은 메탄올로 추출된 것인 약학적 조성물.
- 제1항에 있어서 상기 분획물은 물, C1 ~ C4의 알코올, 클로로포름, 에틸아세테이트, 헥산, 부탄올 또는 이들의 혼합용매를 사용하여 분획한 것인 약학적 조성물.
- 제1항에 있어서, 상기 만성폐쇄성 폐질환은 만성폐쇄성기관지염, 만성세기관지염, 폐기종(Emphysema), 다발성 경화증, 급성 및 만성 염증으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것인 약학적 조성물.
- 제1항에 있어서, 상기 추출물, 분획물 및 화합물은 하기의 활성을 나타내는 것인 약학적 조성물:(a) 기관지 또는 혈관 주위의 염증세포 수 및 호중구의 수 감소;(b) CD4+ 또는 Neutrophils+Gr-1+ 세포 수 감소;(c) CXCL-1의 생성 억제;(d) TNF-α의 생성 억제;(e) MCP-2의 생성 억제.
- 제1항에 있어서, 상기 조성물은 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 1 내지 10 중량%; 또는 이로부터 분리한 화합물을 0.01 내지 10 중량%로 함유하는 것인 조성물.
- 피스타시아 웨인마니폴리아 추출물, 이의 분획물 및 이로부터 분리한 화합물을 포함하는 만성폐쇄성 폐질환의 예방 또는 개선용 식품 조성물.
- 제10항에 있어서, 상기 식품 조성물은 건강기능성 식품인 것인 식품 조성물.
- 제10항에 있어서, 식품학적으로 허용가능한 담체를 추가로 포함하는 만성폐쇄성 폐질환 예방 또는 치료용 식품 조성물.
- 제10항에 있어서, 상기 추출물은 물, C1 ~ C4의 알코올 또는 이들의 혼합용매를 사용하여 추출된 것인 식품 조성물.
- 제10항에 있어서, 상기 추출물은 메탄올로 추출된 것인 식품 조성물.
- 제10항에 있어서 상기 분획물은 물, C1 ~ C4의 알코올, 클로로포름, 에틸아세테이트, 헥산, 부탄올 또는 이들의 혼합용매를 사용하여 분획한 것인 식품 조성물.
- 제10항에 있어서, 상기 만성폐쇄성 폐질환은 만성폐쇄성기관지염, 만성세기관지염, 폐기종(Emphysema), 다발성 경화증, 급성 및 만성 염증으로 이루어진 군으로부터 선택되는 어느 하나 이상인 것인 식품 조성물.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017506239A JP6362764B2 (ja) | 2014-04-17 | 2015-04-17 | ピスタキア ウェインマニフォリア抽出物、その分画物またはこれらから分離された化合物を含む慢性閉塞性肺疾患(copd)の予防または治療用薬学的組成物 |
EP15779202.9A EP3132799B1 (en) | 2014-04-17 | 2015-04-17 | Pharmaceutical composition comprising pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (copd) |
CN201580029098.6A CN106659750B (zh) | 2014-04-17 | 2015-04-17 | 用于预防或治疗慢性阻塞性肺疾病的药物组合物 |
US15/304,316 US10751378B2 (en) | 2014-04-17 | 2015-04-17 | Pharmaceutical composition comprising Pistacia weinmannifolia extract, fraction of same or compound separated from same for preventing or treating chronic obstructive pulmonary disease (COPD) |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20140046105 | 2014-04-17 | ||
KR10-2014-0046105 | 2014-04-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015160219A1 true WO2015160219A1 (ko) | 2015-10-22 |
Family
ID=54324330
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/003881 WO2015160219A1 (ko) | 2014-04-17 | 2015-04-17 | 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 |
Country Status (6)
Country | Link |
---|---|
US (1) | US10751378B2 (ko) |
EP (1) | EP3132799B1 (ko) |
JP (2) | JP6362764B2 (ko) |
KR (1) | KR101647029B1 (ko) |
CN (1) | CN106659750B (ko) |
WO (1) | WO2015160219A1 (ko) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2015160219A1 (ko) * | 2014-04-17 | 2015-10-22 | 한국생명공학연구원 | 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 |
KR102112806B1 (ko) * | 2017-03-15 | 2020-05-19 | 한국생명공학연구원 | 피스타시아 웨인마니폴리아의 미백 및 주름 개선 용도 |
KR102233566B1 (ko) | 2018-05-04 | 2021-03-30 | 서울대학교산학협력단 | 스틸벤 유도체를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
KR102138073B1 (ko) | 2018-05-04 | 2020-07-27 | 서울대학교산학협력단 | 소치논을 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
KR102404684B1 (ko) | 2019-01-15 | 2022-06-07 | 서울대학교산학협력단 | 인슐린 유사 성장인자 2 억제제를 포함하는 만성 폐질환의 예방 또는 치료용 조성물 |
KR102223717B1 (ko) | 2021-01-08 | 2021-03-08 | (주)오성내츄럴바이오 | 만성폐쇄성 페질환 완화 또는 치료용 생약 조성물, 이를 포함하는 한방 약침액 및 이를 포함하는 주사제 |
KR102662544B1 (ko) | 2021-10-19 | 2024-05-03 | 서울대학교산학협력단 | 참문어 추출물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물 |
KR20230055867A (ko) | 2021-10-19 | 2023-04-26 | 서울대학교산학협력단 | 살오징어 추출물을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물 |
KR20230090117A (ko) | 2021-12-14 | 2023-06-21 | 서울대학교산학협력단 | 에보디아민을 유효성분으로 포함하는 만성 폐쇄성 폐질환 예방 또는 치료용 약학적 조성물 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2559434A2 (en) * | 2007-02-12 | 2013-02-20 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004262905A (ja) * | 2003-03-04 | 2004-09-24 | Inabata Koryo Kk | 抗アレルギー剤及び該抗アレルギー剤を含有する食品組成物 |
KR101604347B1 (ko) * | 2013-07-01 | 2016-03-17 | 한국생명공학연구원 | 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 염증성 질환의 예방 또는 치료용 약학 조성물 |
KR20160124188A (ko) | 2014-02-20 | 2016-10-26 | 다케다 파머수티컬 컴패니 리미티드 | 오렉신 수용체 길항제로서의 치환된 시클로펜탄, 테트라히드로푸란 및 피롤리딘 |
WO2015160219A1 (ko) * | 2014-04-17 | 2015-10-22 | 한국생명공학연구원 | 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 |
-
2015
- 2015-04-17 WO PCT/KR2015/003881 patent/WO2015160219A1/ko active Application Filing
- 2015-04-17 EP EP15779202.9A patent/EP3132799B1/en active Active
- 2015-04-17 JP JP2017506239A patent/JP6362764B2/ja active Active
- 2015-04-17 US US15/304,316 patent/US10751378B2/en active Active
- 2015-04-17 KR KR1020150054467A patent/KR101647029B1/ko active IP Right Grant
- 2015-04-17 CN CN201580029098.6A patent/CN106659750B/zh active Active
-
2018
- 2018-05-02 JP JP2018088947A patent/JP6623253B2/ja active Active
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2559434A2 (en) * | 2007-02-12 | 2013-02-20 | Mike Nicolaou | Treatment of COPD using a histidine decarboxylase inhibitor sole or combined with an anti-H1 drug or with a leucotriene receptor antagonist |
Non-Patent Citations (5)
Title |
---|
MDEE, L. K. ET AL.: "Rhuschalcones II-VI, five new bichaleones from the root bark of Rhus pyroides", JOURNAL OF NATURAL PRODUCTS, vol. 66, 2003, pages 599 - 604, XP055231267 * |
MINAMI, K. ET AL.: "Isolation and identification of histamine-release inhibitors from Pistacia weinmannifolia J. Pisson ex. Franch", JOURNAL OF NATURAL MEDICINES, vol. 60, 2006, pages 138 - 140, XP019376646, DOI: doi:10.1007/s11418-005-0017-z * |
QIN, S. ET AL.: "Epigallocatechin-3-gallate reduces airway inflammation in mice through binding to proinflammatory chemokines and inhibiting inflammatory", CELL RECRUITMENT'' THE JOURNAL OF IMMUNOLOGY, vol. 186, 2011, pages 3693 - 3700, XP055359587 * |
RAHMAN, I.: "Pharmacological antioxidant strategies as therapeutic interventions for COPD", BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-MOLECULAR BASIS OF DISEASE, vol. 1822, 2012, pages 714 - 728, XP055231263 * |
ZHAO, X. ET AL.: "Antioxidant properties of two gallotannins isolated from the leaves of Pistacia weinmannifolia", BIOCHIMICA ET BIOPHYSICA ACTA (BBA)-GENERAL SUBJECTS, vol. 1725, 2005, pages 103 - 110, XP027639551 * |
Also Published As
Publication number | Publication date |
---|---|
US10751378B2 (en) | 2020-08-25 |
CN106659750A (zh) | 2017-05-10 |
EP3132799B1 (en) | 2019-06-12 |
CN106659750B (zh) | 2021-02-12 |
KR20150120880A (ko) | 2015-10-28 |
KR101647029B1 (ko) | 2016-08-11 |
EP3132799A4 (en) | 2017-11-29 |
JP2018162247A (ja) | 2018-10-18 |
US20170035822A1 (en) | 2017-02-09 |
JP6623253B2 (ja) | 2019-12-18 |
JP2017513947A (ja) | 2017-06-01 |
JP6362764B2 (ja) | 2018-07-25 |
EP3132799A1 (en) | 2017-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2015160219A1 (ko) | 피스타시아 웨인마니폴리아 추출물, 이의 분획물 또는 이로부터 분리된 화합물을 포함하는 만성폐쇄성 폐질환(copd) 예방 또는 치료용 약학적 조성물 | |
WO2020235928A1 (ko) | 흑삼 추출물을 포함하는 항인플루엔자 바이러스 조성물, 호흡기 질환 치료용 조성물 및 항노화 조성물 | |
WO2014104672A1 (en) | A purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient, the preparation thereof, and the composition comprising the same as an active ingredient for preventing or treating inflammation, allergy and asthma | |
WO2017179931A1 (ko) | 쥐꼬리망초 추출물을 포함하는 호흡기 질환의 예방 또는 치료용 약학적 조성물 | |
WO2020040462A1 (ko) | 식물 추출물을 유효성분으로 하는 미세먼지에 의해 유도된 호흡기질환 예방 또는 치료용 조성물 | |
WO2018208094A2 (en) | A composition comprising a combined herb extract of salvia plebia and red ginseng as active ingredients for preventing or treating a respiratory inflammation and the use thereof | |
WO2012043949A1 (ko) | 화학식 1 내지 8로 표시되는 화합물 또는 고삼 추출물을 유효성분으로 포함하는 면역 증강용 조성물 | |
WO2010090498A2 (ko) | 이고들빼기 추출물, 이의 분획물 또는 이로부터 분리한 화합물을 유효성분으로 함유하는 간 기능 개선용 약학적 조성물 및 간 기능 개선용 건강기능 식품조성물 | |
WO2021071269A1 (ko) | 복합 생약 추출물을 포함하는 염증성 장질환의 예방 또는 치료용 조성물 | |
WO2015002430A1 (ko) | 피스타시아 웨인마니폴리아 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 약학 조성물 | |
WO2021080297A1 (ko) | 달맞이꽃 추출물을 유효성분으로 포함하는 비만 또는 비만으로부터 유도된 대사증후군의 예방 또는 치료용 조성물 | |
WO2017183924A1 (ko) | 단풍나무 잎 추출물을 포함하는 안구건조증의 예방 또는 치료용 조성물 | |
WO2019177428A1 (ko) | 호흡기 질환의 예방 또는 치료용 생약 조성물 | |
WO2012093787A2 (ko) | 플로로글루시놀, 플로로탄닌 또는 갈조류 추출물을 포함하는 가바 a형-벤조다이아제핀 수용체 활성용 조성물 및 불안 완화, 경련 개선, 진정 작용, 및 수면 유도 및 개선용 조성물 | |
WO2017188499A1 (ko) | 글리시리진 및 리퀴리틴 함유 감초 추출물을 포함하는 간질환의 예방 또는 치료용 약학 조성물 | |
WO2018221922A1 (ko) | 황련 추출물을 함유하는 근육관련 질환의 예방 및 치료용 조성물 및 이의 용도 | |
WO2009104913A2 (en) | Composition comprising an extract of mixed herbs with lonicera japonica thunb and anemarrhena asphodeloides bunge for preventing and treating arthritic diseases | |
WO2015105373A1 (ko) | 화살나무 추출물 또는 이의 분획물을 포함하는 천식의 예방 또는 치료용 조성물 | |
WO2010143825A2 (en) | Anti-arthritic agent using cyathula officinalis | |
WO2014168413A1 (en) | The composition comprising a purified extract isolated from pseudolysimachion rotundum var. subintegrum containing abundant amount of active ingredient or the compounds isolated therefrom, as an active ingredient for preventing or treating chronic obstructive pulmonary disease and the use thereof | |
WO2021261660A1 (ko) | 참깨박 추출물의 제조방법 및 이를 유효성분으로 포함하는 대장염 예방 또는 개선용 식품 조성물 | |
WO2016204493A1 (en) | A novel compound (ks 513) isolated from pseudolysimachion rotundum var. subintegrum, the composition comprising the same as an active ingredient for preventing or treating allergy disease, inflammatory disease, asthma or chronic obstructive pulmonary disease and the use thereof | |
WO2016175589A2 (ko) | 혼합 생약 추출물을 함유하는 호흡기 질환 예방 또는 치료용 약학적 조성물 | |
WO2020222470A1 (ko) | 황련 및 형개 혼합 추출물을 유효성분으로 포함하는 염증성 장질환 예방 또는 치료용 약제학적 조성물 | |
WO2018056698A1 (ko) | 식물의 추출 복합물을 포함하는 항염 조성물 및 염증성 질환 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15779202 Country of ref document: EP Kind code of ref document: A1 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15304316 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2017506239 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015779202 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2015779202 Country of ref document: EP |